Pacer Advisors Inc. Sells 30,598 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Pacer Advisors Inc. trimmed its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 80.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,632 shares of the biotechnology company’s stock after selling 30,598 shares during the quarter. Pacer Advisors Inc.’s holdings in ADMA Biologics were worth $151,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ADMA. Tsfg LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth $51,000. Farther Finance Advisors LLC increased its stake in ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 2,505 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in ADMA Biologics in the 4th quarter valued at $85,000. CIBC Private Wealth Group LLC increased its stake in ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 2,954 shares during the last quarter. Finally, Covestor Ltd increased its stake in ADMA Biologics by 7,038.1% in the 4th quarter. Covestor Ltd now owns 5,996 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,912 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company’s stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director directly owned 94,830 shares of the company’s stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,621 shares of company stock valued at $9,644,269. Company insiders own 3.50% of the company’s stock.

ADMA Biologics Stock Up 3.4%

ADMA Biologics stock opened at $19.33 on Friday. The firm has a market capitalization of $4.61 billion, a PE ratio of 22.74 and a beta of 0.38. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The company’s 50-day moving average is $18.81 and its 200-day moving average is $18.77. ADMA Biologics Inc has a fifty-two week low of $10.21 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business’s quarterly revenue was up 40.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 EPS. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several recent research reports. Raymond James Financial lifted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.